CDK9 and lymphoma: This study demonstrates the biologic advantage of a selective CDK9 inhibitor for the treatment of MYC+ lymphoma preclinical models which is confirmed by analysis of blood samples from patients treated with 30 mg enitociclib i.v. once weekly.